beclometasone oral (SGX203) / Soligenix - LARVOL DELTA

Soligenix: Advances two lead programs into phase II within one week (SeekingAlpha) - "Soligenix plans to start Phase II/III trial of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease in 1H 2014. Primary endpoint data are expected in 1H 2015."

Anticipated new P2/3 trial • Anticipated P2/3 data • Anticipated trial initiation date • Inflammatory Bowel Disease

Soligenix reports third quarter 2011 financial results (Soligenix) - Soligenix announced its financial results for Q3 2011; Soligenix announced formation of MAB to provide medical/clinical strategic guidance related to development of SGX203 (oral BDP) for treatment of pediatric CD in Oct 2011; Soligenix’s net income for Q3 2011 was approximately $0.01 per share vs. (loss) of $(0.01) per share for Q3 2010

Financial & pipeline update • Inflammatory Bowel Disease

Corporate Presentation (Soligenix Press Release) - Anticipated P2/3 trial for pediatric Crohn’s in H2 2013. Anticipated P2/3 data of pediatric Crohn’s in H2 2014.

Anticipated new P2/3 trial • Anticipated P2/3 data • Inflammatory Bowel Disease